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RESEARCH PAPER
Early oseltamivir reduces risk for influenza-associated aspergillosis in a 
double-hit murine model
Laura Seldeslachts a, Lore Vanderbekeb, Astrid Fremaua, Agustin Reséndiz-Sharpeb, Cato Jacobsc, Bo Laeverena, 
Tessa Ostyna, Lieve Naesensd, Matthias Brocke, Frank L. Van De Veerdonkf, Stephanie Humblet-Barong, 
Erik Verbekenh, Katrien Lagroub, Joost Wautersc,* and Greetje Vande Velde a,*
aDepartment of Imaging and Pathology, Biomedical MRI unit/MoSAIC, Ku Leuven, Leuven, Belgium; bDepartment of Microbiology, 
Immunology and Transplantation, Laboratory of Clinical Bacteriology and Mycology, Ku Leuven, Leuven, Belgium; cDepartment of 
Microbiology, Immunology and Transplantation,Laboratory for Clinical Infectious and Inflammatory Disorders, Ku Leuven, Leuven, Belgium; 
dDepartment of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy (Rega Institute), Ku Leuven, 
Leuven, Belgium; eFungal Biology Group, School of Life Sciences, University of Nottingham, Nottingham, UK; fDepartment of Internal 
Medicine, Radboud University Medical Center, Nijmegen, Netherlands; gDepartment of Microbiology, Immunology and Transplantation, 
Laboratory of Adaptive Immunity, Ku Leuven, Leuven, Belgium; hDepartment of Imaging and Pathology, Ku Leuven, Leuven, Belgium
ABSTRACT
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection occurring mainly in 
immunocompromised patients. We recently identified IPA as an emerging co-infection with high 
mortality in critically ill, but otherwise immunocompetent influenza patients. The neuraminidase 
inhibitor oseltamivir is the current standard-of-care treatment in hospitalized influenza patients; 
however, its efficacy in influenza-associated pulmonary aspergillosis (IAPA) is not known. 
Therefore, we have established an imaging-supported double-hit mouse model to investigate 
the therapeutic effect of oseltamivir on the development of IAPA. Immunocompetent mice 
received intranasal instillation influenza A or PBS followed by orotracheal inoculation with 
Aspergillus fumigatus 4 days later. Oseltamivir treatment or placebo was started at day 0, day 2, 
or day 4. Daily monitoring included micro-computed tomography and bioluminescence imaging 
of pneumonia and fungal burden. Non-invasive biomarkers were complemented with imaging, 
molecular, immunological, and pathological analysis. Influenza virus-infected immunocompetent 
mice developed proven airway IPA upon co-infection with Aspergillus fumigatus, whereas non- 
influenza-infected mice fully cleared Aspergillus, confirming influenza as a risk factor for develop-
ing IPA. Longitudinal micro-CT showed pulmonary lesions after influenza infection worsening after 
Aspergillus co-infection, congruent with bioluminescence imaging and histology confirming 
Aspergillus pneumonia. Early oseltamivir treatment prevented severe influenza pneumonia and 
mitigated the development of IPA and associated mortality. A time-dependent treatment effect 
was consistently observed with imaging, molecular, and pathological analyses. Hence, our find-
ings underscore the importance of initiating oseltamivir as soon as possible, to suppress influenza 
infection and mitigate the risk of potentially lethal IAPA disease.
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Invasive pulmonary aspergillosis (IPA) is a life- 
threatening fungal infection characterized by acute 
infection of the lungs occurring mainly in immuno-
compromised patients [1]. In the last decade, severe 
influenza has gained a foothold worldwide as an 
emerging risk factor for IPA [1,2]. Recently, we pub-
lished two retrospective case–control studies on 
influenza-associated pulmonary aspergillosis (IAPA) 
[1,3]. IPA was found as a co-infection in 19% of 
patients with severe influenza at a median of 3 days 
after intensive care unit (ICU) admission [1]. 
Remarkably, the cohort of co-infected patients had 
a high mortality risk of 51%, whereas that of severe 
influenza without IAPA was 28% [1]. By June 2018, 
128 IAPA cases were published, with 28% of the 
patients having no underlying medical condition 
[4]. These incidence rates emphasize the importance 
of recognizing influenza as an independent risk fac-
tor for IPA and the high morbidity and mortality 
associated with it. Hence, an international group of 
experts has published a case definition of IAPA to 
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facilitate research in epidemiology, diagnosis, and 
management of this emerging disease [5].
Globally, influenza is estimated to affect 5–10% of 
the population each year. On average, 3–5 million cases 
of severe influenza occur annually worldwide, leading 
to 290,000–650,000 deaths [6,7]. Virus-induced lung 
epithelial damage and host immune response aberra-
tions are hallmark manifestations of severe influenza 
infection [8–11]. These pathological processes are the 
key to success for secondary pathogenic microorgan-
isms to enter the lung parenchyma and colonize 
patients [12]. Bacterial superinfections with 
Staphylococcus aureus and Streptococcus pneumoniae 
are well-defined complications of a severe influenza 
infection and different mouse models of influenza- 
bacterial-co-infection have been developed [13–16]. 
However, until today, influenza-associated fungal co- 
infection models are not yet widely experimentally 
addressed. To preclinically assess potential treatment 
strategies, a robust animal model recapitulating IAPA 
disease in humans is needed.
Currently, the neuraminidase inhibitor (NAI) osel-
tamivir, is the standard-of-care to suppress influenza. 
This drug prevents successful virus replication by inhi-
biting the viral neuraminidase. Several clinical studies 
have corroborated that early oseltamivir treatment 
improves the outcome in critically ill patients suffering 
from influenza [17–19]. Also in mice, oseltamivir is 
known to improve survival, body weight loss, and to 
reduce viral lung titers, thereby limiting the severity of 
lung damage [20,21]. In addition, in a mouse model of 
influenza-bacterial-co-infection both prophylactic and 
early oseltamivir treatments improved the survival and 
reduced the extent of the secondary pneumococcal 
pneumonia [22–24]. Likewise, we hypothesize that osel-
tamivir may reduce the susceptibility to IAPA in mice 
and men through attenuation of influenza infection.
Here, we establish a double-hit mouse model for 
IAPA and report on its imaging capabilities to long-
itudinally follow-up influenza pneumonia and exacer-
bation after challenge with A. fumigatus conidia. In this 
model, we assessed whether IAPA is prevented by osel-




A mouse-adapted influenza virus A/H3N2/Ishikawa/7/ 
82 was kindly provided as a mouse lung homogenate by 
M. Hosoya (Fukushima, Japan) [25]. The virus was 
expanded in Madin–Darby canine kidney (MDCK) 
cells, which were also used to determine the virus titer 
by standard plaque assay. Original virus stocks were 
thawed and diluted to a final concentration of 500 
PFU/mL.
Aspergillus strain
In all experiments, an A. fumigatus derivative of strain 
CBS144.89 expressing a red-shifted thermostable firefly 
luciferase from the akuB locus was used. In brief, 
a codon-optimized red-shifted and thermostable firefly 
luciferase (lucOPT_red_TS, GenBank accession number: 
MT554554) was synthesized (GenScript) and cloned 
under control of the 820 bp promoter of the glyceral-
dehyde-3-phosphate dehydrogenase (gpdA) from 
Aspergillus nidulans and fused with a 322 bp gpdA 
terminator region. This luciferase expression construct 
was cloned into the ptrA-pJET1 plasmid [26] contain-
ing the pyrithiamine resistance gene. The entire 4785 
reporter_ptrA cassette was amplified with oligonucleo-
tides PgpdAIFKu80up_f (5ʹ – CCC TGA GGC GGC 
CGC GGG CTG AGT AAT AAG – 3ʹ) and 
ptrAIFKU80do_r (5ʹ – AAC TTT GGG CGG CCG 
CGT ATT ATA CTG TC – 3ʹ) to allow subsequent 
in vitro recombination with the upstream and down-
stream flanking regions of the akuB gene from 
A. fumigatus. Genomic DNA of the A. fumigatus wild- 
type strain CBS144.89 served as template for amplifica-
tion of the 819 bp upstream and 666 bp downstream 
region of the akuB gene. The akuB upstream region 
was amplified with oligonucleotides KU80upIFpUC_f 
(5ʹ – CGA GCT CGG TAC CCG GGA CTC AAT TTC 
TAT TCT AGA GCA TC- 3ʹ) and KU80upIFPgpdA_r 
(5ʹ – 
GCGGCCGCCTCAGGGTCGTCAAAGTCAGTAC – 
3ʹ). The downstream region was amplified with oligo-
nucleotides KU80doIFptrA_f (5ʹ – GCG GCC GCC 
CAA AGT TAA AGG GCG CAA GC) and 
KU80doIFpUC_r (5ʹ – CTC TAG AGG ATC CCC 
GGG CTA TCA CTT TGC CCA GTC – 3ʹ). 
A pUC19 plasmid was linearized with SmaI and the 
three PCR products were assembled with the plasmid 
by in vitro recombination using the InFusion HD clon-
ing kit (Takara/Clonetech). Assembled plasmids were 
amplified in Escherichia coli DH5α. After isolation of 
the plasmid (NucleoSpin plasmid, Machery-Nagel) the 
entire cassette was excised from the plasmid backbone 
by SmaI restriction and used for protoplast transforma-
tion of the A. fumigatus wild-type strain CBS144.89 
using 0.1 μg pyrithiamine/ml (Sigma) as selection mar-
ker. Transformants were pre-screened by cultivation on 
Aspergillus minimal medium [27] containing 0.2 mM 
D-luciferin (Promega) and imaging of plates in 
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a Chemi Doc XRS system (BioRad) under chemilumi-
nescent setting. Selected transformants were analyzed 
for single copy integration of the reporter construct 
into the akuB locus and strain 
Af_ΔakuB::lucOPT_red_TS_ptrA No. 5 was selected for 
further use. For preparation of conidia suspensions, 
the strain was cultured on Sabouraud agar for 3 days 
at 42°C. A. fumigatus conidia were harvested by detach-
ing with NaCl-0.1% Tween 80 (Sigma-Aldrich, Diegem, 
Belgium) solution, followed by vigorous shaking and 
filtering of the suspension. Finally, spores were counted 
with a Neubauer hemocytometer and diluted to a final 
concentration of 5 × 109 conidia/mL.
Mouse model
All animal experiments were approved by the KU Leuven 
Ethical Committee for animal research (license p074/ 
2018). Eight to ten weeks old immunocompetent male 
C57BL/6NTac mice (internal stock of the Laboratory 
Animal Center, KU Leuven) were kept in 
a conventional animal facility in individually ventilated 
cages with free access to food and water. To prevent 
bacterial infection, an antibiotic (50 mg/kg/day, Baytril®, 
Bayer) was added to the drinking water. Animals were 
randomly assigned to experimental groups. Mice 
received intranasal instillation of 10 plaque forming 
units (PFU) influenza virus or PBS (10 µL per nostril) 
under inhalation anesthesia with isoflurane (1.5–2% in 
oxygen, Primal Critical Care). Mice were orotracheally 
inoculated with 20 µL of A. fumigatus spore solution 
under injection anesthesia (Ketamine (75 µg/g) and 
Medetomidine (1 µg/g)) (Figure 1(a)) or isoflurane 
(Figure 2a, Figure 4a). Oseltamivir (10 mg/kg) or PBS 
treatment was administered twice daily by oral gavage. 
During the experiments, mice were monitored daily for 
body weight, general condition, and respiratory para-
meters, non-invasively scanned with micro-computed 
tomography and bioluminescence imaging and sacrificed 
when the humane or predefined experimental endpoint 
was reached, by an overdose of pentobarbital via intra-
peritoneal injection [28]. Subsequently, blood was drawn 
by cardiac puncture, bronchoalveolar lavage (BAL) fluid 
was obtained by three lung lavages with 700 µL 0.9% 
NaCl and right lung lobes were aseptically collected, 
weighted, and homogenized in PBS. The left lung was 
inflated with 400 µL 10%-formalin, 24 h post fixated and 
then stored in PBS-0.1% sodium-azide at 4°C. 
Subsequently, histopathology analysis was performed. 
BAL and blood were centrifuged at respectively 1000 
x g for 10 min at 4°C and 13,817 x g for 4 min at 4°C. 
BAL supernatant, serum and lung homogenates were 
used for further quantification of virus titers, fungal 
burden, and cytokine analysis.
Micro-computed tomography (µCT)
A dedicated whole-body small animal µCT scanner 
(SkyScan 1278, Bruker micro-CT, Kontich, Belgium) 
was used to acquire lung µCT data of free-breathing 
anesthetized (isoflurane, 1.5–2% in oxygen, Piramal 
Critical Care) animals in supine position. Following 
scan parameters were used: 50 kVp X-ray source, 
1 mm aluminum X-ray filter, 350 µA current and 
150 ms exposure time per projection acquiring pro-
jections with 0.9° increments over a total angle of 
220°. Acquisition resulted in respiratory weighted 
reconstructed 3D dataset with isotropic voxel size of 
50 µm in a total scanning time of 3 min, associated 
with a radiation dose exposure of 69–89 mGy [29]. 
Temperature, respiration rate, and visual information 
were used to monitor mice while scanning. µCT data 
was reconstructed, visualized, and processed using 
NRecon, DataViewer, and CTan software, provided 
by the manufacturer. Reconstruction parameters 
were: smoothing 2, beam hardening correction of 
10%; post alignment and ring artifact reduction 
were optimized for each individual scan. µCT data 
were processed and calibrated to Hounsfield units 
(HU) as described before [30]. In brief, regions of 
interests (ROI), resulting in a volume of interest 
(VOI) covering the entire lung, were manually deli-
neated on transverse images, thereby avoiding the 
heart and main blood vessels [30,31]. Subsequently, 
imaging-derived biomarkers of lung pathology (total 
lung volume (TLV), aerated lung volume (ALV), 
non-aerated lung volume (NALV) and mean lung 
densities) were quantified. To distinguish ALV from 
NALV, a fixed manually set threshold of 94 HU was 
used based on histogram in CTan (TLV ranges from 
−1000 to 1160, ALV from −1000 to (−94), NALV −85 
to1160). Visual observations of transverse µCT 
images were semi-quantitatively scored by two 
blinded researchers (LS and BL) according to [31] 
with minor modifications. In brief, four transverse 
images at different, defined positions in the lung 
were selected for each animal at each time point on 
the reconstructed µCT. Per animal, a score of zero 
was assigned to each image at baseline. Subsequently, 
scores of +0.25, 0 or −0.25 depending on observed 
worsening, stabilization, or improvement of pulmon-
ary lesions (pulmonary infiltrate), respectively, were 
assigned and added to the score of the previous day 
to obtain a cumulative score.
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Figure 1. Second-hit with A. fumigatus during active influenza infection drives risk for clinical deterioration with IPA. (a) experimental 
setup for the development of double-hit mouse model: immunocompetent mice received influenza A virus on day 0, followed by 
orotracheal inoculation with A. fumigatus conidia on day 3, 4, 5, 6 or day 7 post-influenza infection. control groups of mock-infected 
(sham), influenza only and aspergillus only were included. body weight was measured daily. (b) body weight evolution of sham- 
infected and infected mice. (c) maximum body weight loss per animal for different experimental arms. red box represents mice 
which were sacrificed because humane endpoints were reached (d) grocott’s methenamine silver staining of left lungs from mice 
with A. fumigatus, influenza-A. fumigatus day 3 co-infected, influenza-A. fumigatus day 4 co-infected mice sacrificed at 
respectively day 7 and day 8 post influenza infection (magnification ×400). Aspergillus conidia (red box) and hyphae (yellow box).
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Bioluminescence imaging (BLI)
For in vivo BLI, the mice were intraperitoneally injected 
with D-luciferin (in PBS, 50 mg/mL, 500 mg/kg), then 
anesthetized (isoflurane inhalation, 1.5–2% in oxygen, 
Piramal Critical Care) and placed in supine position in 
an IVIS Spectrum System (Perkin-Elmer, Hopkinton, 
MA, USA). Five consecutive images were acquired 
Figure 2. Immunocompetent mice develop IPA in a background of a sublethal influenza-pneumonia. (a) experimental setup: 
immunocompetent mice received influenza A virus on day 0 followed by orotracheal inoculation with A. fumigatus conidia 
on day 3 and 4 post-influenza infection. sacrifice was performed 2 days after co-infection. Single control groups of either mock 
infected (sham) and influenza alone with sacrifice on day 6 were included. (b) body weight evolution of immunocompetent mice 
infected with influenza on baseline (day 0) and co-infected with a. fumigatus 3 or 4 days later. Parallel sham-infected and influenza- 
infected mice were included as controls. (c) graph representing the log10 CCID50 per gram lung tissue from sham-infected (sacrificed 
on d6), influenza-infected (sacrificed on d6), influenza – A. fumigatus day 3 (sacrificed on d5) and influenza-A. fumigatus day 4 co- 
infected mice (sacrificed on d6). (d) Log10 colony forming unit (CFU) count per gram lung tissue from influenza-A. fumigatus day 3 
(sacrifice d5) and influenza-A. fumigatus day 4 co-infected mice (sacrifice d6). (e) Scatter plot of cytokine response (IL-1β and IL-6) in 
serum and bronchoalveolar lavage fluid (BALF) of mock infected (sham), influenza infected and influenza-Aspergillus day 4 co- 
infected mice sacrifice on day 6. dashed line represents lower detection limit of the standards (LDL). In influenza-A. fumigatus day 4 
co-infected mice. all graphs are represented as mean or as mean ± SD, **** P < 0.0001.
VIRULENCE 2497
starting 10 min after injection. Following settings were 
used: exposure time of 1 min, medium binning, F/stop 
of 1 and subject height of 1.5 cm. Quantification of BLI 
data reflecting fungal lung burden was performed with 
software provided by the manufacturer (Living Image 
Software version 4.7.3). Total photon flux (p/s) was 
measured through a ROI of 6.9 cm2, covering the 
lungs, and the maximum from consecutive acquisitions 
used for further analysis.
For ex vivo BLI, 1:5 serial dilutions of homogenized 
right lung lobes in black 96-well plates (Nunc® Microwell, 
Thermo Fisher Scientific, Merelbeke, Belgium) were 
placed in the IVIS Spectrum after addition of 10% 
D-luciferin (in PBS, 50 mg/mL). Images were acquired 
until maximum signal intensity was reached with follow-
ing settings: exposure time of 1 min per image, medium 
binning, F/stop of 1 and subject height of 1 cm. ROIs, 
covering one well, were created to measure total photon 
flux. The highest total photon flux from consecutive 
acquisitions was used for further analysis.
Quantification of virus and fungal titers
Serial dilutions of right lung homogenates were also 
used to assess the fungal load by colony-forming unit 
(CFU) counting. Dilutions were plated on Sabouraud 
agar plates and incubated at 37°C for 48 h. Reported 
CFU counts represent average values of duplicate plat-
ing of each dilution. DNA was extracted from lung 
homogenates and BAL fluid, for subsequent 
AsperGenius® multiplex real-time PCR assay, as pre-
viously described [32]. For influenza virus titration, 
serial dilutions of right lung homogenate supernatants 
were added to MDCK cells in quadruplicate. After 72 h 
incubation at 35°C, viral cytopathic effect was assessed 
by microscopic scoring. Virus titers were calculated by 
the method of Reed and Muench as log10 CCID50/g of 
lung tissue [33].
Cytokine analysis
Cytokine levels were quantified in BAL fluid and serum 
using an electrochemiluminescence based V-PLEX 
Proinflammatory Panel 1 Mouse kit from Meso Scale 
Diagnostics (MSD) [34].
Histopathology
Left lung 5-µm paraffin sections were cut and stained 
with hematoxylin-eosin and Grocott’s methenamine 
silver staining. Staining were scored by a blinded 
pathologist (EV).
Statistical analysis
Statistics were performed using GraphPad Prism (ver-
sion 8.1.2, GraphPad Software, San Diego, CA, USA). 
Longitudinal and end point data were analyzed with, 
respectively, two-way ANOVA or one-way ANOVA 
with Tukey’s multiple comparisons test (repeated mea-
surements performed from day 0 to day 4 and day 4 
to day 7). All graphs represent mean values ± SD. 
P values are indicated in figures and are described in 
full in figure or figure legends and differences were 
considered significant if p was smaller or equal to 
0.05. *P < 0.05, **P < 0.01, ***P < 0.001, **** 
P < 0.0001. n values represent the number of animals.
Results
Immunocompetent mice develop IPA in 
a background of a sublethal influenza-pneumonia
We first set out to investigate the risk of developing 
IPA in the setting of an influenza virus infection. To 
determine the effect of timing of secondary 
Aspergillus infection toward developing IAPA, mice 
were co-infected with conidia of a bioluminescent 
A. fumigatus strain at day 3, 4, 5, 6, or 7 post- 
influenza virus infection (Figure 1(a), Suppl Fig. 
S1). Mice infected with influenza virus alone showed 
moderate body weight loss and clinical worsening 
up to day 8 followed by recovery toward day 12 in 
all mice. Likewise, mice infected with only 
A. fumigatus showed limited transient body weight 
loss without overt clinical illness, and all these ani-
mals fully recovered. In contrast, infection with 
influenza virus followed by A. fumigatus resulted in 
faster and more substantial body weight loss as well 
as more severe clinical deterioration in some but not 
all mice (Figure 1(b-c)). In day 3 or day 4 co- 
infected fatally ill mice, histopathological examina-
tion confirmed the presence of hyphae invading the 
airway wall indicating airway invasive pulmonary 
aspergillosis which is in sharp contrast with 
Aspergillus only infected mice where only 
Aspergillus conidia were present (Figure 1(d)).
Given the observed disease severity in these mice, 
similarity with early IAPA development in critically 
ill influenza patients in ICU and therapeutic window 
for immune modulation in future research, in a next 
experiment, we zoomed in on the pathology of 
Aspergillus co-infection 3 and 4 days after influenza 
infection (Figure 2(a)). Consistently, these co- 
infected animals showed markedly faster reduced 
body weight as well as clinical deterioration imme-
diately after Aspergillus inoculation in comparison 
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with influenza-only infected mice (Figure 2(b)). 
At day 2 post A. fumigatus infection, we measured 
extensive fungal load and high viral load (Figure 2 
(c-d)). In influenza- A. fumigatus day 4 co-infected 
mice, sacrificed at day 6, the cytokine profile showed 
a strong inflammatory burden with high levels of IL- 
1β and IL-6 in BAL fluid and serum which could 
point toward a possible myeloid activation (Figure 2 
(e), Suppl Fig. S2). Furthermore, histopathology 
of day 4 co-infected mice exhibited severe diffuse 
acute purulent mainly neutrophilic bronchitis and 
pneumonia with epithelial erosion at day 6 (2 days 
post A. fumigatus infection) (Figure 3(a)). In con-
trast, single infection with influenza virus resulted in 
diffuse bronchiolitis with epithelial damage and 
multifocal lymphocytic alveolitis at day 6 (Figure 3 
(a)). Histopathology further confirmed the presence 
of A. fumigatus conidia with hyphae invading the 
airway wall in all day 4 (Figure 3(a)) and some of 
the day 3 co-infected mice (data not shown). 
Together, these data demonstrate that sublethal 
influenza pneumonia predisposes to airway invasive 
pulmonary aspergillosis in immunocompetent mice.
Oseltamivir modulates severity of influenza 
infection and mitigates the susceptibility to IPA in a 
time-dependent manner
Having established a double-hit mouse model of IAPA, 
we next explored the efficacy of oseltamivir in modu-
lating the susceptibility to develop IPA. The antiviral 
drug was started at day 0, 2, 4 after influenza virus 
infection (Figure 4(a)). The non-treated day 4 co- 
infected mice experienced severe body weight loss 
by day 4, significantly worsening toward day 7, and 
all these animals had to be euthanized by day 8 or 9 
(Figure 4(b-c)). In sharp contrast, oseltamivir initiated 
at day 0 or 2 generated a survival rate of 100%, in line 
with significantly less body weight loss and body weight 
recovery from day 7 onwards (Figure 4(b-c)). Also, 
mice treated from day 4, lost significantly less body 
weight loss in comparison with the non-treated group 
was seen toward day 7 (Figure 4(b)). Hence, oseltamivir 
proved highly effective the earlier the treatment was 
started.
We further analyzed the precise impact of oseltami-
vir on the severity of influenza-pneumonia through 
longitudinal non-invasive µCT. Toward day 4 (during 
Figure 3. Histopathological confirmation of airway invasive pulmonary aspergillosis in influenza Aspergillus day 4 co-infected mice. 
(a) Hematoxylin and eosin (H&E) of left lung of (on the top) single infection with influenza virus (magnification ×50, ×200) showing 
a diffuse bronchiolitis with epithelial damage and multifocal lymphocytic alveolitis at day 6 and (on the bottom) influenza- 
Aspergillus day 4 co-infected mice sacrificed at day 6 (magnification ×100, ×400) showing a severe diffuse acute purulent mainly 
neutrophilic bronchitis and pneumonia with epithelial erosion at day 6. grocott’s methenamine silver staining (GMS) of influenza- 
Aspergillus day 4 co-infected mice sacrificed at day 6 (magnification x400). Black arrows represent hyphae invading the airway wall.
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influenza infection and before Aspergillus co-infection), 
semi-quantitative scores derived from µCT-thorax 
scans revealed multifocal hyperdense pulmonary 
lesions in the lungs of non-treated mice, while oselta-
mivir treated mice remained largely spared from lesions 
development the earlier oseltamivir was started 
(Figure 5(a-b) Suppl Fig. S3). In support of these visual 
observations, non-aerated lung volume, a quantitative 
biomarker of pulmonary infiltrates and consolidation, 
was markedly lower in oseltamivir versus non-treated 
mice (Figure 5(c)). Accordingly, the aerated lung 
volume was consistently higher in drug-treated animals 
(Figure 5(d)). Together, these results showed substan-
tially reduced severity of influenza pneumonia the ear-
lier the start of oseltamivir treatment.
Toward day 7 (i.e. 3 days after co-infection with 
Aspergillus), we observed that oseltamivir suppressed 
or even prevented disease exacerbation resulting from 
IAPA. Obvious consolidation of entire lung lobes and 
bronchial dilation was seen in non-treated mice 
Figure 4. Oseltamivir treatment improves survival and body weight reduction. (a) experimental setup of the establishment of the 
relationship between influenza and risk to IPA through modulation of influenza by antiviral treatment oseltamivir: immunocompe-
tent mice received influenza A on day 0, followed by inoculation with A. fumigatus on day 4. oseltamivir (10 mg/kg) or PBS treatment 
twice daily by oral gavage was started at day 0 (n = 10), day 2 (n = 10) or day 4 (n = 5) up to predefined experimental endpoint (day 
7 or day 12) or when humane endpoints were reached. during the experiment, mice were monitored daily (body weight, general 
condition, respiratory parameters) while performing micro-computed tomography (µCT) and bioluminescence imaging (BLI). (b) 
Body weight evolution of immunocompetent influenza- Aspergillus day 4 co-infected mice without oseltamivir (blue, n = 10), 
oseltamivir treatment from day 4 (orange, n = 5), oseltamivir treatment from day 2 (red, n = 10), oseltamivir treatment from day 0 
(green, n = 10). Longitudinal Statistical analysis: two-way ANOVA with Tukey’s multiple comparisons test repeated measurements 
performed from day 0 until day 4 (*** p = 0,0001; * (orange, green) p = 0,0416; * p (red, green) = 0,0220) and day 4 until day 7 (**** 
P < 0.0001, ** p = 0,0092, * p = 0,0453) (c) Kaplan-Meier survival curve of influenza-aspergillus day 4 co-infected mice with no 
oseltamivir (blue, n = 5), oseltamivir treated from day 2 (red, n = 5) and oseltamivir treated from day 0 (green, n = 5). all graphs are 
represented as mean ± SD.
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Figure 5. µCT revealed longitudinal visualization and quantification of the disease process of IAPA and the alleviated or abolished 
effect from oseltamivir treatment. (a) Longitudinal transversal lung µCT images of sham-treated (no oselt), oseltamivir treated 
from day 4 (oselt d4), oseltamivir treated from day 2 (oselt d2) and oseltamivir treated from day 0 (oselt d0) double-infected mice 
and coronal images on day 7. Blue arrow: pulmonary infiltrates, red arrow: bronchial dilation (b) Semi-quantification of image score 
of transverse lungs µCT images (no oseltamivir, blue, n = 10; oseltamivir d4, orange, n = 5; oseltamivir d2, red, n = 10; oseltamivir d0, 
green, n = 10). Statistical analysis: two-way ANOVA with Tukey’s multiple comparisons test repeated measurements performed 
from day 0 until day 4 (* p = 0,0257) and day 4 until day 7 (* (red, green) p = 0,0158; * (blue, orange) p = 0,0349; **** P < 0.0001) 
(c-d) graph represents quantification of biomarkers non-aerated lung volume (c) and aerated lung volume (d) from transverse lung 
µCT images (no oseltamivir, blue, n = 10; oseltamivir d4, orange, n = 5; oseltamivir d2, red, n = 10; oseltamivir d0, green, n = 10). 
Statistical analysis for all longitudinal graphs: two-way ANOVA with Tukey’s multiple comparisons test repeated measurements 
performed from day 0 until day 4 (C = non-aerated lung volume: * p = 0,0388; D = aerated lung volume: * (red, green) p = 0,0359, * 
(orange, green) p = 0,0484, * (blue, green) p = 0,0137) and day 4 until day 7 (C = non-aerated lung volume: * (orange, green) 
p = 0,0106, * (red, green) p = 0,0185, ** (blue, orange) p = 0,0080, **** P < 0.0001; D = aerated lung volume: * p = 0,0444, ** 
p = 0,0068, **** P < 0.0001). Graphs are represented as mean ± SD. (e) Spearman correlation between % body weight change 
on day 4 and non-aerated lung volume on day 7. The spearman’s correlation coefficient and corresponding P-value are given on the 
graph.
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(Figure 5(a-b) Suppl Fig. S3). On the contrary, less to 
no pulmonary infiltrates were present in mice treated 
with oseltamivir, and this was more prominent the 
earlier treatment was started (Figure 5(a-b) Suppl Fig. 
S3). During Aspergillus co-infection (between day 4 
and day 7), non-treated mice showed significant gra-
dual increase in non-aerated and decreased aerated 
lung volume in comparison with treated mice (day 0 
– day 2) (Figure 5(c-d)). Overall, the earlier treatment 
was initiated, the more significant these differences 
became. Although oseltamivir treated mice (day 4) do 
have a significantly lower non-aerated lung volume, 
there was no difference in aerated lung volume in 
comparison with non-treated mice (Figure 5(c-d)). 
Finally, by pooling the data from all mice, we observed 
that the non-aerated lung volume on day 7, strongly 
correlated with the body weight reduction on day 4 
(r = −0,8255; P < 0.0001) (Figure 5(e)). Collectively, 
our analysis of lung abnormalities using imaging and 
µCT-derived biomarkers demonstrated that oseltamivir 
modulates the severity of influenza and subsequent 
Aspergillus co-infection in a time-dependent manner 
during IAPA infection.
Next, we explored the impact of oseltamivir on 
IAPA by longitudinal follow-up of fungal burden 
through bioluminescence-based imaging (BLI) and 
microbiological gold-standard techniques. Toward day 
7 (3 days post Aspergillus co-infection), in vivo biolu-
minescence signal intensity was lower in oseltamivir- 
treated conditions compared to non-treated mice; how-
ever, almost all mice elicited comparable ex vivo biolu-
minescent signal and fungal burden (CFU count) 
(Figure 6(a-d)). Moreover, histopathology detected 
clear morphological differences between treated and 
non-treated mice: all mice treated with oseltamivir pre-
sented with lymphocytic inflammation combined with 
macrophages with intracellular A. fumigatus conidia, 
whereas non-treated mice showed a diffuse acute puru-
lent neutrophilic inflammation with A. fumigatus 
hyphae invading the airway wall (Figure 7(a), Suppl. 
Table. S1).
At later time points, clearance of fungal infection 
became increasingly evident in oseltamivir treated ani-
mals and at endpoint, CFU counts and ex vivo BLI 
signals were significantly lower (compared to non- 
treated), in agreement with higher Ct-values when 
detection was done by PCR (Figure 6(c-e)). Again, 
these findings nicely correlated with the histopathology 
since mice treated with oseltamivir from day 0 or day 2 
manifested, respectively, no or only slight lymphocytic 
inflammation with notable signs of epithelial recovery 
(Figure 7(b), Suppl. Table. S1). In addition, very local 
or no A. fumigatus conidia were perceived (Figure 7 
(b)). On the contrary, in non-treated mice, we observed 
mainly neutrophilic inflammation in bronchovesicular 
bundles and alveolar parenchyma with clear diffuse 
epithelial damage and bronchitis accompanied by 
A. fumigatus hyphae invading the airway wall (Suppl. 
Table. S1). Finally, mean clinical score on day 4 corre-
lated with ex vivo bioluminescence on endpoint 
(r = 0.6455, P < 0.0001) (figure 6(f)). To conclude, 
early oseltamivir prevented severe lung pathology 
from influenza virus-Aspergillus co-infection and facili-
tated the pathogen clearing process.
Discussion
Here, we report the establishment of the first imaging- 
supported mouse model for the sequential interaction 
between influenza and Aspergillus fumigatus, experi-
mentally confirming influenza as an independent risk 
factor for the development of IAPA in an immunocom-
petent host. Furthermore, we demonstrated that early 
oseltamivir treatment modulates the severity of influ-
enza and mitigates the susceptibility to IAPA in a time- 
dependent manner. We herewith identify an early treat-
ment to reduce the incidence of IAPA.
Until now, mouse models for influenza-associated 
co-infections have been limited to bacterial infections 
and more recently to Cryptococcus [35,36]. Although 
several clinical reports revealed influenza as an inde-
pendent risk factor for IPA and a case definition of 
IAPA was published [1,4,5], animal models for super-
infection by Aspergillus spp. were lacking. We provide 
a robust mouse model that corroborates our earlier 
retrospective data on IAPA in critically ill patients 
with severe influenza and confirm that IAPA develops 
in immunocompetent mice even without corticoster-
oids [1]. In line with the findings from Tobin et al. 
(2020) [38]. In our model, immunocompetent mice 
showed severe body weight loss and clinical deteriora-
tion when first infected with influenza virus and super-
infected 4 days later with A. fumigatus conidia, whereas 
single infection with influenza or Aspergillus alone gen-
erated only transient disease. High titers of virus and 
fungus were present at 2 days after co-infection, point-
ing to an important link between high viral replication 
and increased susceptibility to IPA, similarly observed 
in other influenza models with fungal or bacterial co- 
infection [35,37].
Immunocompetent mice can spontaneously clear In 
line with the findings from Tobinet al. (2020) [38] 
A. fumigatus conidia, with complete restoration of 
lung tissue architecture, although proinflammatory 
cytokines, neutrophil infiltrates, Aspergillus conidia 
and CFUs were reported to be present during the first 
2502 L. SELDESLACHTS ET AL.
Figure 6. Oseltamivir treatment mitigates the risk to develop IPA. (a) Bioluminescence images (BLI) of double-infected mice acquired 
on day 7, 8 and day 12 post influenza. (b) in vivo BLI: quantification of total photon flux from BLI images based on region of interest 
(ROI) covering the complete lung region of influenza-Aspergillus day 4 co-infected mice without oseltamivir (blue, n = 10), 
oseltamivir treatment from day 4 (orange, n = 5), oseltamivir treatment from day 2 (red, n = 10), and oseltamivir treatment 
from day 0 (green, n = 10). Longitudinal Statistical analysis: two-way ANOVA with Tukey’s multiple comparisons test repeated 
measurements performed from day 4 until day 8 (*** (green, black) p = 0,0002; ** (blue, red) p = 0,0024, *** (blue, green) 
p = 0,0006) and day 4 until day 12 (*** p (red, black) = 0,0006). (c) ex vivo BLI: scatter plot represents the quantification of total 
photon flux from BLI images based on ROI covering the well containing undiluted lung homogenates on day 7 and endpoint (no 
oseltamivir day 8, oseltamivir treated groups day 12) from influenza-A. fumigatus day 4 co-infected mice without oseltamivir, 
oseltamivir treatment from day 4, oseltamivir treatment from day 2, and oseltamivir treatment from day 0, **** P < 0.0001. (d) Graph 
representing the log10 CFU count per gram lung tissue from influenza-Aspergillus day 4 co-infected mice without oseltamivir, 
oseltamivir treatment from day 4, oseltamivir treatment from day 2, and oseltamivir treatment from day 0, on day 7 and endpoint 
(no oseltamivir d8, oseltamivir groups d12), **** P < 0.0001. (e) Representative A. fumigatus quantification with AsperGenius qPCR 
from influenza-A. fumigatus day 4 co-infected without oseltamivir, oseltamivir treatment from day 2, and oseltamivir treatment 
from day 0 at endpoint (no oseltamivir d8, oseltamivir groups d12), **** P < 0.0001. (f) Spearman correlation between the log10 total 
flux from ex vivo BLI on experimental endpoint or humane endpoint and mean clinical score on day 4 of influenza-A. fumigatus day 4 
co-infected without oseltamivir, oseltamivir treatment from day 4, oseltamivir treatment from day 2, and oseltamivir treatment 
from day 0. The spearman’s correlation coefficient and corresponding P-value are given on each graph. All graphs are represented as 
mean ± SD.
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Figure 7. Oseltamivir treated mice are able to clear A. fumigatus in lungs. (a) Histological hematoxylin and eosin (H&E) (left, 
magnification ×50, ×200) and grocott’s methenamine silver staining (GMS) (right, magnification ×400) staining of left lung of 
different groups (no oseltamivir, oseltamivir treatment from day 4, oseltamivir treatment from day 2, oseltamivir treatment 
from day 0) sacrificed on day 7. Hyphae (black arrow), intracellular conidia (arrowhead). (b) Histological H&E (left, magnification 
×50, ×200) and GMS (right, magnification ×200) staining of left lung of different groups (oseltamivir treatment from day 2 and 
oseltamivir treatment from day 0) sacrificed on day 12.
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three days of infection [39–41]. By using longitudinal 
imaging, we further uncovered the disease progression 
in co-infected mice. Notable multifocal lesions were 
present over the course of influenza infection, which 
worsened into consolidation of total lung lobes and 
high fungal burden after co-infection with 
A. fumigatus. Corresponding to the lesions on µCT, 
severe diffuse acute purulent mainly neutrophilic bron-
chitis and pneumonia with epithelial erosion were dis-
covered with histopathology. Despite the 
immunocompetent status, all influenza virus pre- 
infected mice developed proven airway invasive asper-
gillosis when co-infected with A. fumigatus on day 4, in 
sharp contrast to the animals infected with A. fumigatus 
only, which proved fully capable of clearing the fungus. 
Hence, we experimentally corroborate influenza as 
a strong risk factor for developing IPA, which is inde-
pendent of other immunosuppressive regimens or 
conditions.
There is ample evidence from clinical studies that 
early oseltamivir treatment improves the outcome in 
patients with severe influenza, by reducing the dura-
tion of hospitalization, complications, and hospital 
mortality [17–19,42,43]. The importance of early 
influenza treatment was also seen in a ferret model 
[44]. Likewise, oseltamivir is capable of reducing the 
viral load and the severity of lung infection/lung 
damage [20,21]. On top of this evidence, we observed 
that oseltamivir not only reduces the severity of 
influenza, but also mitigates the susceptibility to 
IAPA. As far as we know this has never been demon-
strated so far. However, a pre-requisite is that oselta-
mivir started early enough. This conclusion is 
supported by our comprehensive clinical, radiologi-
cal, pathophysiological and microbial analysis. First, 
early oseltamivir fully prevented the fatal outcome of 
IAPA. Secondly, antiviral therapy resulted in less 
pulmonary infiltrates, less severe influenza pneumo-
nia and smaller lesions on µCT after A. fumigatus co- 
infection. Thirdly, the increase in fungal burden was 
strongly (or even completely) inhibited in mice that 
received early oseltamivir. Finally, histopathological 
examination of lung tissue damage confirmed that 
the drug-treated mice were able to completely 
recover from this serious co-infection. To conclude, 
early oseltamivir administration in mice with sub-
lethal influenza successfully lowers the susceptibility 
to develop IAPA. Our pre-clinical findings warrant 
future clinical studies focusing on reducing IAPA 
incidence, by impacting on influenza severity via 
oseltamivir.
Regarding Aspergillus clearing, we observed that 
oseltamivir-treated mice carried macrophages with 
intracellular conidia of Aspergillus at 3 days after its 
inoculation. This concurs with an active antifungal 
immune response where macrophages phagocytose 
Aspergillus conidia [45]. Remarkably, we did not 
observe this in non-treated mice suggesting that influ-
enza might cause some immune dysregulation, which is 
prevented by early treatment with oseltamivir. 
Influenza is known to induce a strong IFN-γ/Th1 
response decreasing the macrophage phagocytic activity 
in an influenza/Streptococcus pneumoniae model sec-
ondary to a downregulation of a scavenger molecule 
(MARCO) at the cell surface [15]. Considering the 
histology findings in our model, the latter hypothesis 
could be appropriate with a severe reduction in phago-
cytic properties in mice co-infected with influenza and 
A. fumigatus while this phagocytic function could be 
restored once the viral burden decreases after oseltami-
vir treatment. However, our observations argue for 
a more comprehensive study. The transient presence 
of Aspergillus conidia inside macrophages also provides 
an explanation for why bioluminescence signals and 
CFU counts were positive yet consistently low on day 
7, but negative on day 12. Thus, oseltamivir treatment 
reduces the severity of the infectious pathology and 
drives/facilitates an active antifungal clearing process.
Importantly, the timing of oseltamivir treatment 
remains essential. Early treatment reduces influenza 
disease symptoms accompanied by a decreasing risk 
of acquiring IAPA. However, once IAPA is present, it 
is not clear whether neuraminidase inhibition is bene-
ficial or detrimental. There is evidence that blocking 
neuraminidase activity in a murine model of aspergil-
losis is detrimental [46,47]. Blocking neuraminidase 
might have a negative impact on anti-Aspergillus host 
defense itself [48–50]. However, our results show that 
this possibly negative effect on the fungal host response 
will probably be balanced out by the positive effect on 
influenza.
In conclusion, we established the first successful 
preclinical imaging-supported double-hit mouse 
model of IAPA. This model recapitulates and con-
firms influenza as a risk factor for the development 
of invasive and potentially fatal pulmonary aspergil-
losis. We demonstrated that early oseltamivir treat-
ment mitigates the risk to develop IAPA. Besides 
reinforcing the recommendation to start oseltamivir 
as soon as possible (within 48–72 h) in case of 
severe influenza our findings indicate that early 
onset of oseltamivir might also reduce the high 
mortality and morbidity associated with IAPA [1]. 
In a broader context, this double-hit mouse model is 
the key for future research aimed at unraveling the 
underlying immune mechanism of IAPA.
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